Items where authors include "Andronis, L."

Article

Zanganeh, M. orcid.org/0000-0003-3934-6044, Belcher, J. orcid.org/0000-0001-6844-0932, Fotheringham, J. orcid.org/0000-0002-8980-2223 et al. (15 more authors) (2024) Cost-effectiveness of bioimpedance-guided fluid management in patients undergoing haemodialysis: the BISTRO RCT. Health Technology Assessment. pp. 1-45. ISSN 1366-5278

James, N., Pirrie, S., Pope, A. et al. (17 more authors) (2016) TRAPEZE: a randomised controlled trial of the clinical effectiveness and cost-effectiveness of chemotherapy with zoledronic acid, strontium-89, or both, in men with bony metastatic castration-refractory prostate cancer. Health Technology Assessment, 20. 53. ISSN 1366-5278

Andronis, L., Goranitis, I., Pirrie, S. et al. (19 more authors) (2016) Cost-effectiveness of zoledronic acid and strontium-89 as bone protecting treatments in addition to chemotherapy in patients with metastatic castrate-refractory prostate cancer: results from the TRAPEZE trial (ISRCTN 12808747). BJU International. ISSN 1464-4096

James, N.D., Pirrie, S.J., Pope, A.M. et al. (19 more authors) (2016) Clinical Outcomes and Survival Following Treatment of Metastatic Castrate-Refractory Prostate Cancer With Docetaxel Alone or With Strontium-89, Zoledronic Acid, or Both. JAMA Oncology, 2 (4). p. 493. ISSN 2374-2437